Literature DB >> 33987290

Fugitive aerosols in the intensive care unit: a narrative review.

Ciarraí O'Toole1, Mary Joyce2, James A McGrath1, Andrew O'Sullivan2, Miriam A Byrne1, Ronan MacLoughlin2,3,4.   

Abstract

The risk of unintended inhalation of fugitive aerosols is becoming a topic of increasing interest in the healthcare arena. These fugitive aerosols may be bioaerosols, generated by the patient themselves through cough or sneeze, or they may be therapeutic medical aerosols, generated by therapeutic medical aerosol generators with the intent of delivery to a specific patient's respiratory tract. This review focus' on therapeutic aerosols in the intensive care unit (ICU) only, those typically generated by nebulisers. In the intensive care environment, patients are generally in receipt of ventilatory support, and the literature suggests that these different support interventions influence fugitive therapeutic medical aerosol emissions in a variety of ways. Predominant ventilatory support interventions include, but are not limited to, invasive mechanical ventilation (MV), non-invasive mechanical ventilation (NIV), high flow nasal therapy (HFNT), and supplemental oxygen delivery in spontaneously breathing patients. Further, factors such as nebuliser type, patient interface, patient breathing pattern, nebuliser position in the patient breathing circuit and medication formulation characteristics also have been shown to exert influence on aerosol concentrations and distance from the source. Here we present the state of the art knowledge in this, as yet, poorly described field of research, and identify the key risks, and subsequently, opportunities to mitigate the risks of unintended exposure of both patients and bystanders during and for periods following the administration of therapeutic aerosols. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Aerosols; exposure; fugitive; intensive care unit (ICU); jet nebulizer (JN); secondary inhalation; vibrating mesh nebuliser (VMN)

Year:  2021        PMID: 33987290      PMCID: PMC8105852          DOI: 10.21037/atm-20-2280

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  31 in total

1.  Aerosolized MMR vaccine: evaluating potential transmission of components to vaccine administrators and contacts of vaccinees.

Authors:  Jose-Luis Diaz-Ortega; John V Bennett; Deyanira Castaneda; David Martinez; Jorge Fernandez de Castro
Journal:  Biologicals       Date:  2012-04-10       Impact factor: 1.856

2.  Inhaled Antibiotics for Hospital-Acquired and Ventilator-Associated Pneumonia.

Authors:  Lindsay M Daniels; Jonathan Juliano; Ashley Marx; David J Weber
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

3.  Reduction of Contamination with Antibiotics on Surfaces and in Environmental Air in Three European Hospitals Following Implementation of a Closed-System Drug Transfer Device.

Authors:  Paul J M Sessink; Tibor Nyulasi; Emmie L M Haraldsson; Branislava Rebic
Journal:  Ann Work Expo Health       Date:  2019-04-19       Impact factor: 2.179

4.  Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin.

Authors:  Bart P H Wittgen; Peter W A Kunst; Walter R Perkins; Jin K Lee; Pieter E Postmus
Journal:  J Aerosol Med       Date:  2006

5.  Performance of two respiratory protective devices used by home-attending health care workers (a pilot study).

Authors:  Reported By Yousef Elmashae; Sergey A Grinshpun; Tiina Reponen; Michael Yermakov; Robert Riddle
Journal:  J Occup Environ Hyg       Date:  2017-09       Impact factor: 2.155

6.  Exposure of health care workers to pentamidine isethionate.

Authors:  J R Beach; M Campbell; D J Andrews
Journal:  Occup Med (Lond)       Date:  1999-05       Impact factor: 1.611

7.  Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks.

Authors:  David S Hui; Benny K Chow; Thomas Lo; Owen T Y Tsang; Fanny W Ko; Susanna S Ng; Tony Gin; Matthew T V Chan
Journal:  Eur Respir J       Date:  2019-04-11       Impact factor: 16.671

8.  Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children.

Authors:  V L Montgomery; N S Eid
Journal:  J Asthma       Date:  1994       Impact factor: 2.515

9.  A local exhaust ventilation system to reduce airborne ribavirin concentrations.

Authors:  D Matlock; R M Buchan; M Tillery
Journal:  Am Ind Hyg Assoc J       Date:  1991-10

10.  High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection.

Authors:  J A Englund; P A Piedra; Y M Ahn; B E Gilbert; P Hiatt
Journal:  J Pediatr       Date:  1994-10       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.